NCT06533631 Measuring Brain Health Using Low-Field Portable MRI
| NCT ID | NCT06533631 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yale University |
| Condition | White Matter Hyperintensity |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-02-05 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-02-05 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to develop a new grading scale and utilize automated segmentation for measurement of White Matter Hyperintensity (WMH) volume using a low field MRI.
Eligibility Criteria
Inclusion Criteria: * One vascular risk factor, from the following: 1. Hypertension (defined as taking an antihypertensive medication) 2. Hyperlipidemia (defined as taking a statin or PCSK9 inhibitor) 3. Diabetes (defined as taking a medication to prevent hyperglycemia) Exclusion Criteria: * 1\. History of stroke * History of dementia or other cognitive impairment * Pacemaker or other MRI contraindications according to the American College of Radiology guidelines
Contact & Investigator
Adam H de Havenon, MD
PRINCIPAL INVESTIGATOR
Yale University
Frequently Asked Questions
Who can join the NCT06533631 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying White Matter Hyperintensity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06533631 currently recruiting?
Yes, NCT06533631 is actively recruiting participants. Contact the research team at adam.dehavenon@yale.edu for enrollment information.
Where is the NCT06533631 trial being conducted?
This trial is being conducted at New Haven, United States.
Who is sponsoring the NCT06533631 clinical trial?
NCT06533631 is sponsored by Yale University. The principal investigator is Adam H de Havenon, MD at Yale University. The trial plans to enroll 100 participants.